Literature DB >> 7826526

Recent developments in the radioimmunotherapy of cancer.

J G Jurcic1, D A Scheinberg.   

Abstract

Recent trials using radiolabeled monoclonal antibodies, particularly for hematologic neoplasms, have demonstrated the ability of these agents to destroy tumor cells safely and specifically. Advances in molecular biology, immunology and radiochemistry will allow the continued development of strategies to overcome the remaining obstacles to effective therapy with radioimmunoconjugates.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7826526     DOI： 10.1016/0952-7915(94)90074-4

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  4 in total

1.  An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.

Authors:  J C Becker; N Varki; S D Gillies; K Furukawa; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

2.  Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

Authors:  J C Becker; J D Pancook; S D Gillies; J Mendelsohn; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

3.  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Authors:  J L Casey; D J King; L C Chaplin; A M Haines; R B Pedley; A Mountain; G T Yarranton; R H Begent
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

4.  Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts.

Authors:  E Kievit; H M Pinedo; H M Schlüper; H J Haisma; E Boven
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.